Natco Pharma unveils Chlorantraniliprole (CTPR) formulated product NATGEN in India

Published On 2022-09-26 07:10 GMT | Update On 2022-09-26 07:10 GMT

Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company has launched Chlorantraniliprole (CTPR) 18.5% SC under the Brand Name of NATGEN in the Indian Market.

NATCO is the 1st Company in India to have received its registration approval given by the Central Insecticide Board & Registration Committee (CIB&RC), recorded in its Minutes of the 425th Meeting held on January 25th, 2021, for the indigenous manufacture of Chlorantraniliprole (CTPR) Technical 93.00% w/w min. under Section 9(3).

CTPR technical is formulated into broadspectrum insecticides used across a wide range of crops for pest management.

NATCO estimates the current market size of CTPR-containing products in India to be over INR 2000 crores.

Natco Pharma Limited is a vertically integrated and R&D-focused pharmaceutical company engaged in developing, manufacturing, and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.

Natco sells its FDF products in the United States, India, Europe, and the rest of the world ("RoW"). In the API segment, the company has capabilities to develop and manufacture products with multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides.

The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Natco Pharma unveils Chlorantraniliprole (CTPR) formulated product NATGEN in India

Similar News

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

CBI Cracks Down on PCI Chief Montu Patel in College Bribery Scandal

Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

Over 700 bottles of Codeine Cough Syrup seized, 2 arrested

Massive Rs 1.2 crore Oxytocin seizure in Lucknow, 3 held

High-Alcohol Medicinal Preparations to Come Under Schedule H1: Govt Panel Approves Rule Change